Connective tissue disease-associated interstitial lung disease (CTD-ILD; incl. RA, scleroderma, myositis)
ctd-ild · Respiratory
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Interstitial lung disease arising with systemic autoimmune disease - systemic sclerosis, rheumatoid arthritis, idiopathic inflammatory myositis (incl. anti-synthetase, anti-MDA5), Sjogren, mixed connective tissue disease, SLE. Distinct from IPF: many are inflammation-predominant and respond to immunosuppression, while progressive fibrotic phenotypes may need antifibrotics. Needs combined respiratory-rheumatology care.
Red flags
- Rapidly progressive ILD, esp. anti-MDA5 dermatomyositis (can be fulminant - urgent aggressive immunosuppression)
- Acute exacerbation of fibrotic ILD
- New/worsening hypoxaemia
- Pulmonary hypertension (scleroderma)
- Opportunistic infection during immunosuppression (e.g. PJP)
- Scleroderma renal crisis precipitated by high-dose steroids
Assessment
Differential diagnosis
- Idiopathic pulmonary fibrosis / idiopathic interstitial pneumonias
- Hypersensitivity pneumonitis
- Drug-induced ILD (e.g. methotrexate, biologics)
- Infection (incl. opportunistic in immunosuppressed, e.g. PJP)
- Pulmonary involvement of vasculitis
- Heart failure
- ILD as first presentation of occult CTD (interstitial pneumonia with autoimmune features)
Investigations
- HRCT thorax - pattern recognition (NSIP common in scleroderma/myositis; UIP more in RA); extent guides prognosis
- Pulmonary function tests + DLCO (restrictive, reduced gas transfer) - serial testing tracks progression
- Full autoimmune serology: ANA, ENA panel, anti-Scl-70/RNA-pol III/centromere, RF/anti-CCP, myositis panel (Jo-1, anti-MDA5, others), anti-Ro/La
- Exclude infection (esp. before/while immunosuppressing) incl. PJP risk assessment
- Echocardiography (screen pulmonary hypertension, esp. scleroderma)
- 6-minute walk + oxygen saturation; baseline bloods for immunosuppression monitoring
- MDT review (respiratory + rheumatology + radiology); lung biopsy rarely needed if CTD and pattern concordant
Management
- Confirm ILD on HRCT/PFTs and establish the underlying CTD (serology + systemic features); involve rheumatology
- Characterise phenotype: inflammatory-predominant vs progressive fibrotic, and assess severity/trajectory with serial PFTs
- Exclude infection and drug-induced ILD before escalating immunosuppression
- Immunosuppression is first-line for most inflammatory CTD-ILD: corticosteroids plus a steroid-sparing agent (mycophenolate often first choice; cyclophosphamide or rituximab for severe/rapidly progressive, e.g. scleroderma or anti-MDA5 disease)
- Add an antifibrotic (nintedanib) for progressive pulmonary fibrosis phenotype despite treatment (approved for SSc-ILD and progressive fibrosing ILD)
- Caution with high-dose steroids in systemic sclerosis (scleroderma renal crisis risk)
- Supportive care: oxygen if hypoxaemic, pulmonary rehabilitation, vaccination, PJP prophylaxis when heavily immunosuppressed, screen/treat pulmonary hypertension and reflux
- Monitor response and toxicity with serial PFTs/HRCT; refer refractory/advanced disease for transplant assessment
Drugs & doses
Prednisolone (moderate dose) for inflammatory CTD-ILD; avoid high doses in systemic sclerosis (renal crisis risk) [verify dose]
Mycophenolate mofetil titrated to ~1-1.5 g PO BD - common first-line steroid-sparing agent [verify dose]
Cyclophosphamide (IV pulses) or rituximab for severe/rapidly progressive disease (e.g. scleroderma, anti-MDA5 myositis) [verify protocol]
Nintedanib 150 mg PO BD - antifibrotic for SSc-ILD and progressive fibrosing ILD (GI/hepatic monitoring) [verify eligibility]
Co-trimoxazole 480-960 mg daily/alternate days as PJP prophylaxis during significant immunosuppression [verify dose]
Supplemental oxygen if chronic hypoxaemia; PPI for reflux (esp. scleroderma)
Disposition
Specialist respiratory-rheumatology MDT, usually outpatient. Admit rapidly progressive ILD, acute exacerbation, or respiratory failure (urgent immunosuppression). Transplant referral for advanced/refractory disease.
Complications & pitfalls
- Progressive fibrosis and respiratory failure
- Acute exacerbation of ILD (high mortality)
- Pulmonary hypertension / cor pulmonale
- Immunosuppression-related infection and drug toxicity
- Lung cancer risk in fibrotic lung
- Reduced quality of life, need for transplantation
Exam pearls
- Unlike IPF, many CTD-ILDs are inflammation-predominant and respond to immunosuppression - distinguishing phenotype is key (ATS/ERS; scleroderma-ILD evidence from SLS-II/SENSCIS).
- Mycophenolate is a common first-line agent; rituximab/cyclophosphamide for severe or rapidly progressive disease.
- Nintedanib slows decline in systemic-sclerosis-associated and other progressive fibrosing ILDs (SENSCIS/INBUILD) - used alongside immunosuppression for the fibrotic phenotype.
- Avoid high-dose corticosteroids in systemic sclerosis - they can precipitate scleroderma renal crisis.
- Anti-MDA5 dermatomyositis can cause fulminant, rapidly progressive ILD needing urgent aggressive therapy.
- Always exclude infection and drug-induced ILD before intensifying immunosuppression; manage via a respiratory-rheumatology MDT.
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.